SGLT2 inhibitors offer clear and powerful protection against kidney disease progression in people with and without diabetes

A landmark meta-analysis conducted by the Nuffield Department of Population Health and the SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists Consortium (SMART-C), published in The Lancet, has demonstrated the SGLT2 inhibitors have clear and powerful effects on reducing kidney disease progression, regardless of diabetes. 

The study entitled “Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials” provides compelling evidence that SGLT2 inhibitors reduce the risk of not only kidney and cardiovascular outcomes in patients with type 2 diabetes, but also offer similar benefits in patients without diabetes.

The study analyzed data from 13 trials involving 90,413 patients, representing the largest and most comprehensive assessment of the effects of SGLT2 inhibitors on kidney outcomes ever undertaken. The results indicate that SGLT2 inhibitors reduce the risk of kidney disease progression by 37% and acute kidney injury by 23% compared to placebo, with consistent benefits across people with and without diabetes, as well as among those with chronic kidney disease or heart failure.

These findings provide high-quality evidence supporting the use of SGLT2 inhibitors as foundational therapy for reducing risk of kidney disease progression and acute kidney injury, regardless of diabetes status or primary kidney diagnosis.

The publication of this study in The Lancet underscores SMART-C’s commitment to providing definitive and reliable information about the effects of SGLT2 inhibitors on key outcomes in major patient groups.

To read the full publication in The Lancet, click here.